Distinct Type 1 Immune Networks Underlie the Severity of Restrictive Lung Disease after COVID-19
Glenda Canderan(University of Virginia), Judith A. Woodfolk(University of Virginia), Paul J. Utz(Stanford University), Jie Sun(Carter Center), Shay Ladd(University of Virginia), Catherine A. Bonham(MACOM (United States)), Lyndsey M. Muehling(University of Virginia), Alexandra Kadl(University of Virginia), Jeffrey M. Sturek(Carter Center), In Su Cheon(Carter Center), Jonathan M. Irish(Vanderbilt University), Coleen A. McNamara(Carter Center), Sepideh Dolatshahi(Science for Life Laboratory), Claire E. Cross(Vanderbilt University), Deborah D. Murphy(University of Virginia), Naomi Bryant, Sierra M. Lima(Vanderbilt University), Xihui Yin(Stanford University), Behnam Keshavarz(University of Virginia), Jeffrey M. Wilson(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2020|1k
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
Web‐Based Analysis and Publication of Flow Cytometry Experiments
|Current Protocols in Cytometry|2010|530
Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line
|Cell Death and Differentiation|2002|504